HEALTH● LOWAug 12 · Aug 12, 2026, 11:29 AM
Neurocrine slips as safety issues linked to Vykat XR resurface
Seeking Alpha Tech
Neurocrine's stock has declined due to resurfacing safety issues associated with its drug, Vykat XR. This indicates potential concerns for both the company's performance and patient health.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH14m agoKenya records second Ebola case as outbreak in Congo keeps growingEuroNews [en]HEALTH24m agoI work in the NHS and Malawi – we need to urgently rethink how we see health spendingThe Independent WorldHEALTH1h agoVaccines, antibiotics: Africa's push for pharma independence [Business Africa]Africanews [en]HEALTH1h agoNumber of people receiving weight loss jabs on NHS in Scotland revealedthenational.scot · United Kingdom